NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

MTA Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal guidance 90)

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

This is a review of TA guidance 90. Therefore there was no scoping workshop. There was a draft scope consultation and no equality issues were raised during this consultation.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No equality issues were raised in the submissions, expert statements and academic report.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No further equality issues were identified

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other

groups? If so, what are the barriers to access for the specific group?

No equality issues were identified, nor raised in consultation on the draft guidance.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

Not applicable, no issues identified in question 4

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

No equality issues were identified.

Approved by Programme Director (name): Meindert Boysen

Date: 15 Dec 2010

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No equality issues were raised in consultation on the draft guidance.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The recommendations did not change after consultation.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

The recommendations did not change after consultation.

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

No equality issues were identified.

Approved by Programme Director (name): Meindert Boysen

Date: 15 Dec 2010